Please login to the form below

AMD

This page shows the latest AMD news and features for those working in and with pharma, biotech and healthcare.

Joerg Moeller to head Bayer R&D after operational shake-up

The company has suffered a few R&D disappointments of late, however, including the failures of a Regeneron-partnered combination therapy for age-related macular degeneration (AMD) and a drug-device

Latest news

Regeneron and Bayer drop AMD combination

Regeneron and Bayer drop AMD combination. Abandon plans after disappointing phase II trial results. ... advance the duo into phase III in either AMD or diabetic macular oedema.
Novartis buys two firms in pre-Christmas shopping spree

Those only gathered pace after a late-stage setback for age-related macular degeneration (AMD) therapy Fovista (pegpleranib), which was licensed by the company in 2014 in a deal valued at
Novartis' AMD drug pegpleranib fails phase III programme

or wet forms of AMD provided no additional benefit over Lucentis given alone. ... AMD affects up to 25 million people worldwide and is the leading cause of early blindness in the industrialised world.
Better together?

the treatment of AMD.
Xarelto leads the charge at Bayer

There were also gains for Eylea (aflibercept) for age-related macular degeneration (AMD) as well as prostate cancer drug Xofigo (radium Ra 223 dichloride) and Adempas (riociguat) for pulmonary artery hypertension.

More from news
Approximately 23 fully matching, plus 77 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

In the EU, where there’s a high prevalence of AMD, Bayer has enjoyed great success with Eylea - growing revenues by 18% in 2017, ”says Alice Stevens, analyst, cardiovascular and metabolic ... The company plans to launch the highly anticipated
Working with our healthcare system more closely is vital

to essential treatment, expanding and improving care for people living with a leading cause of vision loss – age-related macular degeneration (AMD).
Deal Watch November 2015

The acquisition brings an ophthalmology focus with products for Stargardt's macular degeneration, dry AMD, and myopic macular degeneration. ... 380. Ocata Therapeutics. Astellas Pharma| Laurel. Acquisition - company. Regenerative medicine pipeline focus
Pharma deals during May 2014

Coincidentally two weeks earlier, there was another deal for a product for treating AMD. ... Regeneron also has a time limited first right of negotiation to Avalanche's VEGF agent in phase IIa for AMD.
Deal Watch table for March 2014

22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐ endoglin antibodies, including TRC105 for wet AMD (p2).

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

Gyroscope Therapeutics appoints CEO

Gyroscope has a unique translational approach to tackling complex diseases such as dry AMD for which there are no therapies today.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Programme Executive: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Senior Medical Writer: Great salary and bebefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Scientific Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Account Manager – Med Comms – London: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Senior Medical Writer: Great salary and benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...